Cobimetinib
Cotellic · MEK inhibitor
Real-world AKI signal with BRAF partners.
Matulane · Procarb
Hydrazine alkylating agent · approved 1969 · 4 citations · FAERS AKI reporting ROR 1.92 (95% CI 1.61–2.28, 130 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A classic lymphoma alkylator listed among the cytotoxics with recognized renal complications.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Not well quantified at the drug-specific level. Procarbazine appears in classic onconephrology reviews of the renal complications of cytotoxic therapy as an agent with recognized renal/urological complications, and it is part of multi-agent lymphoma regimens in which acute renal failure (often multifactorial — tumor lysis, volume depletion, combined nephrotoxins) is described. Discrete procarbazine-attributable nephrotoxicity is largely case-/review-level rather than quantified.Source: Healy & Clarkson, Aust N Z J Med 1983 (renal complications of cytotoxic therapy)
Tumor-lysis AKI within days in bulky disease; hypersensitivity-type injury after re-exposure.
Distilled from: “Variable; tumor-lysis-related AKI within days of starting in bulky disease, hypersensitivity-type injury after re-exposure.”
Hypersensitivity-type injury has been described after re-exposure.
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Oral hydrazine-derivative alkylating agent that is metabolically activated (CYP- and oxidation-dependent) to reactive methyldiazonium species that methylate DNA and generate hydrogen peroxide, causing DNA strand breaks. A monoamine-oxidase inhibitor with dietary/drug interactions. Long-standing component of lymphoma regimens (MOPP) and brain-tumor therapy (PCV).
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Interstitium
Supporting tissue around the tubules
Class-level context for the major non-renal toxicities of the Hydrazine alkylating agent class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
4 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 7,315 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
964 of 7,315 reports
Reported with hospitalization
1,355 of 7,315 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 139 of the 7,315 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Procarbazine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Cotellic · MEK inhibitor
Real-world AKI signal with BRAF partners.
Braftovi · BRAF inhibitor
Class tubular signal; usually mild.
Nidran · Nitrosourea (alkylating)
Water-soluble nitrosourea; renal risk inferred at class level; cumulative delayed tubulointerstitial injury; DLT is myelosuppression.
Muphoran · Nitrosourea (alkylating)
Class delayed cumulative tubulointerstitial/ATN; usually mild; acute signal often really cisplatin.
Quadramet · Bone-seeking radiopharmaceutical (153Sm-EDTMP)
Renally excreted; dominant toxicity is reversible myelosuppression; caution in renal impairment.
BRAF/MEK inhibitor
Tubulointerstitial AKI; vemurafenib strongest.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Procarbazine’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Procarbazine; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 7 clinical records among all 22 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.